A ‘business case is an argument, usually documented, that is intended to convince a decision maker to approve some kind of financial, economic or social action to articulate a clear path to an attractive return on investment (ROI) in either financial or social benefit terms, or preferably both’ (extract from INSPIRE Project, ‘D3.1 Economic Determinants of PCP’; GA: 611714).
Deliverable 6.1 aims to present the potential impact that a rapid diagnosis tool, composed of innovative solutions and technologies to be procured for antibiotic stewardship of Ventilator Associated Pneumonia (VAP), could represent for the cross-border Buyer’s Group and at an overall scale. Several fields are considered in order to provide a comprehensive overview (i.e. clinical pathway and operational framework to be addressed within the health care systems, economic dimension).
From the economic perspective, estimated figures are provided in order to exemplify the burden that HAIs and AMR impose on institution (hospitals), patients and society, as well as the potential benefits of the incorporation of rapid diagnostic test to innovate the care delivery and management for ventilated patients at the ICU. The main burden and expenditure is driven due to the complications, including toxicity of antibiotic treatment, time to recovery and the excess time in ICU and hospital stay. In addition, there is a indirect consequence due to the build up of anti microbial resistance.
Lastly, important potential boundaries to adopt the solutions are considered, along with an exercise of risk identification and management.